Dwarka, New Delhi-110077, India
+1(919)321-6187

ASCO and ESMO Abstracts 2020

ASCO and ESMO Abstracts

ASCO Abstracts 2020

 

ASCO: Results of IMpower110 study

Abstract No : 9594

Abstract Type : Poster Session

Indication : Non-Small Cell Lung Cancer

Intervention : Atezolizumab (atezo) vs chemotherapy

Company : F. Hoffmann-La Roche, Ltd

Technology : Monoclonal antibody

QLQ-C30 and QLQ-LC13 completion rates were high at BL and most study visits. TTD of lung cancer-related symptoms was similar in both arms, indicating pts’ low BL symptom burden was maintained for a similar duration. Pts receiving atezo vs chemo sustained numerical improvements in physical function and no worsening in lung cancer-related symptoms.

Read More: https://www.delveinsight.com/asco-conference/article/NCT02409342

 

ASCO: Results from CARTITUDE-1

Abstract No : 8505

Abstract Type : Oral Abstract Session

Indication : Multiple Myeloma

Intervention : JNJ-4528

Company : Janssen Research & Development, LLC

Technology : CAR T Cell Therapy

JNJ-4528 treatment led to responses in all pts. These responses were early, deep, and durable at a low dose of CAR-T cells with 26/29 (90%) pts progression free at median 9-mo follow-up. CRS was manageable in most pts, supporting outpatient dosing.

View More: https://www.delveinsight.com/asco-conference/article/NCT03548207

 

ASCO: Results of IMvigor130

Abstract No : 5011

Abstract Type : Clinical science symposium

Indication : Urothelial Carcinoma

Intervention : Atezolizumab

Company : Roche

Technology : Monoclonal antibody

These results reinforce the potential predictive nature of biomarkers associated with response/resistance to atezo and highlight potentially distinct biology driving benefit with atezo and atezo + PBC. These findings suggest a possible biomarker-directed approach to 1L mUC tx that warrants mechanistic interrogation and prospective validation.

Read More: https://www.delveinsight.com/asco-conference/article/imvigor130

 

ESMO Conference 2020:

 

CheckMate-649 Results at ESMO 2020

Abstract No : Abstract: #LBA6

Indication : Gastric Cancer, Gastroesophageal junction cancer and Esophageal Cancer

Intervention : Nivolumab

Company : Bristol-Myers Squibb

Technology : PD-1/PD-L1 inhibitor

CheckMate-649

NIVO is the first PD-1 inhibitor to demonstrate superior OS and PFS in combination with chemo vs chemo alone in previously untreated pts with advanced GC/GEJC/EAC, with a manageable safety profile. NIVO + chemo represents a potential newstandard 1L treatment option for these pts.

Read More: https://www.delveinsight.com/esmo-conference-2020/article/checkmate-649-NCT02872116-esmo-2020

 

ADAURA trial results at ESMO

ADAURA is a randomized, double-blinded, global, placebo-controlled phase III trial in the adjuvant treatment of 682 patients with stage IB, II, IIIA EGFRm NSCLC resulting in the complete tumor resection and adjuvant chemotherapy as indicated. Patients were treated with Tagrisso 80mg once-daily oral tablets or placebo for three years or until disease recurrence.

View More: https://www.delveinsight.com/esmo-conference-2020/article/ADAURA-trial-results-presented-at-esmo-2020

 

Keynote -361 Trial:  Fails to Meet Primary Endpoints

“Danube phase III with dual checkpoint blockade versus standard chemo fails to improve outcomes. Keynote 361 IO vs. Chemo also negative. Perhaps Javelin 100 is positive because it’s already selected patients who responded to chemo for the use of maintenance IO”

Read More: https://www.delveinsight.com/esmo-conference-2020/article/urothelial-carcinoma-esmo-2020

Leave a comment